Amgen Gets Breakthrough Therapy Designation for Advanced Gastric Cancer Treatment
By Kimberly Chin
Amgen Inc. has received a breakthrough therapy designation by
the U.S. Food and Drug Administration for a treatment that helps
patients with advanced gastric or gastroesophageal cancer.
The drug, bemarituzumab, has shown clinically meaningful
outcomes in patients with this kind of cancer, the company said.
The designation, which helps expedite the development and
regulatory review of medicines, paves the way for the drug to be
used as a first-line treatment in combination with modified
fluoropyrimidine, leucovorin and oxaliplatin, or FOLFOX6, the
Bemarituzumab is the second therapy in Amgen's oncology
portfolio to receive such designation in the past six months, Amgen
Write to Kimberly Chin at firstname.lastname@example.org
(END) Dow Jones Newswires
April 19, 2021 16:37 ET (20:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.